Showing posts with label Maudsley Guidelines 2018. Show all posts
Showing posts with label Maudsley Guidelines 2018. Show all posts

Tuesday, 10 May 2022

Drugs used to Treat Antipsychotic-Induced Weight-Gain (Mnemonic)

Drugs used to Treat Antipsychotic-Induced Weight-Gain (Mnemonic)

The following mnemonic is for the drugs used to treat antipsychotic-induced weight gain. The list is not based on priority; however, metformin is the preferred choice, especially when there is comorbid polycystic ovary disease. Orlistat, with calorie restriction, is also an effective choice.


  • Fluoxetine 
  • Orlistat
  • Reboxetine
  • Metformin, methylcellulose, melatonin
  • Topiramate
  • Bupropion 

Sunday, 10 January 2021

Pharmacological Treatment Algorithm for Treatment Refractory Depression

Pharmacological Treatment Algorithm for Treatment-Refractory Depression

These recommendations are based on the Maudsley Prescribing Guidelines 2018, according to which, depression is treatment refractory when it does not respond to sequential trials of three different antidepressants as recommended in their algorithms. 

In the first three steps below, we have enlisted the recommended pharmacological treatment options for an episode of depression. subsequently, we list the options for treatment-refractory depression. Maudsley Prescribing Guidelines focus on the pharmacological treatment options and algorithms, never nevertheless, they acknowledge the important role of non-pharmacological interventions in its treatment and recommend considering one of the appropriate options like cognitive behaviour therapy and/or behavioural activation and other factors identified as being responsible for resistance.

Step 1:

Recommend an SSRI or mirtazapine. monitor for signs and effects for 3- to 4 weeks. 

Step 2:

if no effects are appreciated, increase the dose, if appropriate (eg for escitalopram, sertraline etc) else, switch to another antidepressant (eg if the patient is on fluoxetine, where dose escalation does not produce any beneficial effects).  

Step 3:

Consider vortioxetine, agomelatine, or mirtazapine, if not already tried.
  1. Vortioxetine
  2. Agomelatine
  3. Mirtazapine

Fourth line 

Augment with either lithium or low-dose quetiapine/aripiprazole, OR Combine mirtazapine (with SSRI or venlafaxine), bupropion (with SSRI), olanzapine (with fluoxetine)
(or first line for refractory depression):

Mnemonic: AV BLOQ

● Aripiprazole augmentation
● Venlafaxine (in combination with mirtazapine)
● Bupropion (+SSRI)
● Lithium augmentation
● Olanzapine and fluoxetine
● Quetiapine augmentation


  • Augment with anyone of an antipsychotic (risperidone), T3, buspirone, lamotrigine, OR
  • Give Ketamine IV or intranasal esketamine, OR
  • Start ECT, OR
  • Give high-dose venlafaxine (above 200mg)

Saturday, 9 January 2021

Treatment of Guidelines for Psychotic Depression

Treatment of Guidelines for Psychotic Depression


Tricyclic with olanzapine or quetiapine

Second choice        



Electroconvulsive therapy           

Guidelines for the Pharmacotherapy of Major Depressive Disorder

Guidelines for the Pharmacotherapy of Major Depressive Disorder

I have summarised the following recommendations from the Maudsley prescribing guidelines in Psychiatry, 13th Ed.


Supportive psychotherapy, CBT, interpersonal therapy, marital/couple therapy, dynamic psychotherapy, behavioral activation

Depressive episode


SRI/ Mirtazapine

à A generic SRI; use mirtazapine if sleep needed



  à Most evidence is for a switch to vortioxetine

Step 3

Mirtazapine, vortioxetine, agomelatine

 à if not already trialed

Featured Post

ICD-11 Criteria for Gambling Disorder (6C50)

ICD-11 Criteria for Gambling Disorder (6C50) A collection of dice Foundation URI : 6C50 Gambling d...